As with any protocol these compounds dosage and what other compounds to take with it are important, there are no single magic bullet mono-therapies.
For example Ivermectin because of its antis-spike protein properties combined with doxycycline has evidence of being efficacious with prion based diseases. Doxycycline has excellent fibril disaggregation properties as well as down regulation of hyperphosphorylation of the Tau protein.
Doxycycline has evidence of being efficacious with prion-based diseases. Doxycycline has excellent fibril disaggregation properties as well as downregulation of hyperphosphorylation of the Tau protein.
Medina L, González-Lizárraga F, Dominguez-Meijide A,
et al. Doxycycline interferes with tau amyloid aggregation
abolishing its associated neuronal toxicity. bioRxiv. 2020.
Doxycycline interferes with tau amyloid aggregation abolishing its associated neuronal toxicity
Doxycycline interferes with tau amyloid aggregation abolishing its assoc...
Tauopathies are neurodegenerative disorders with increasing incidence and still without cure. The extensive time...
Balducci C, Forloni G. Doxycycline for Alzheimers disease
fighting β-amyloid oligomers and neuroinflammation.
They certainly can't reverse if the genetic material integrates into the genome. However certain symptoms can at least be treated.
Dr Cory , Dr. Marick et al have had success with using Ivermectin for post vaccine injury
https://covid19criticalcare.com/wp-content/uploads/2022/11/I-RECOVER-Post-Vaccine-Treatment-Summary.pdf
As with any protocol these compounds dosage and what other compounds to take with it are important, there are no single magic bullet mono-therapies.
For example Ivermectin because of its antis-spike protein properties combined with doxycycline has evidence of being efficacious with prion based diseases. Doxycycline has excellent fibril disaggregation properties as well as down regulation of hyperphosphorylation of the Tau protein.
Doxycycline has evidence of being efficacious with prion-based diseases. Doxycycline has excellent fibril disaggregation properties as well as downregulation of hyperphosphorylation of the Tau protein.
Medina L, González-Lizárraga F, Dominguez-Meijide A,
et al. Doxycycline interferes with tau amyloid aggregation
abolishing its associated neuronal toxicity. bioRxiv. 2020.
Doxycycline interferes with tau amyloid aggregation abolishing its associated neuronal toxicity
Doxycycline interferes with tau amyloid aggregation abolishing its assoc...
Tauopathies are neurodegenerative disorders with increasing incidence and still without cure. The extensive time...
Balducci C, Forloni G. Doxycycline for Alzheimers disease
fighting β-amyloid oligomers and neuroinflammation.
Frontiers in Pharmacology. 2019; 10: 738.
https://www.frontiersin.org/articles/10.3389/fphar.2019.00738/full
Gautieri A, Beeg M, Gobbi M, et al. The anti-amyloidogenic
action of doxycycline a molecular dynamics study on the
interaction with Aβ42. International Journal of Molecular
Sciences. 2019; 20: 4641.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769662/
Dominguez-Meijide A, Parrales V, Vasili E, et al. Doxycycline
inhibits α-synuclein-associated pathologies in vitro and in
vivo. Neurobiology of Disease. 2021; 151: 105256.
Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo - PubMed
Doxycycline inhibits α-synuclein-associated pathologies in vitro and in ...
Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are neurodegenerative disorders characterized by th...
La Vitola P, Artioli L, Cerovic M, et al. Repositioning
doxycycline for treating synucleinopathies Evidence from a
pre-clinical mouse model. Parkinsonism Related Disorders.
2023; 106: 105229.
Repositioning doxycycline for treating synucleinopathies: Evidence from a pre-clinical mouse model - PubMed
Repositioning doxycycline for treating synucleinopathies: Evidence from ...
Our findings promote Doxy as a valuable multi-target therapeutic approach counteracting both symptoms and neurop...
Paldino E, Balducci C, La Vitola P, et al. Neuroprotective
effects of doxycycline in the R6/2 mouse model of Huntingtons
disease. Molecular neurobiology. 2020; 57: 1889-1903.
Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington’s Disease
Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntin...
Mechanisms of tissue damage in Huntington’s disease involve excitotoxicity, mitochondrial damage, and inflammati...
Lavigna G, Masone A, Bouybayoune I, et al. Doxycycline
rescues recognition memory and circadian motor rhythmicity
but does not prevent terminal disease in fatal familial insomnia
mice. Neurobiology of Disease. 2021; 158: 105455.
https://pubmed.ncbi.nlm.nih.gov/34358614/
Varges D, Manthey H, Heinemann U, et al. Doxycycline
in early CJD a double-blinded randomised phase II and
observational study. Journal of Neurology Neurosurgery
Psychiatry. 2017; 88: 119-125.
Doxycycline in early CJD: a double-blinded randomised phase II and observational study - PubMed
Doxycycline in early CJD: a double-blinded randomised phase II and obser...
EudraCT 2006-003934-14; Results.
. Lu Y, Yang Y, Chen W, et al. Minocycline but not doxycycline
attenuates NMDA-induced Ca2+i and excitotoxicity.
NeuroReport. 2020; 32: 38-43.
Minocycline, but not doxycycline attenuates NMDA-induced [Ca2+]i and excitotoxicity - PubMed
Minocycline, but not doxycycline attenuates NMDA-induced [Ca2+]i and exc...
Minocycline and doxycycline, two semisynthetic second-generation tetracyclines, are reported to provide neuropro...
. Noble W, Garwood CJ, Hanger DP. Minocycline
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2712603/
Medina L, González-Lizárraga F, Dominguez-Meijide A,
et al. Doxycycline interferes with tau amyloid aggregation
abolishing its associated neuronal toxicity. bioRxiv. 2020.